Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care29(Suppl. 1), S43–S48 (2006).
   PubMed Web of Science ®Google Scholar
• Weyer C, Maggs DG, Young AA et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in Type 1 and Type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr. Pharm. Des.7(14), 1353–1373 (2001).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ321(7258), 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group: overview of 6 years’ therapy of Type II diabetes: a progressive disease. Diabetes44, 1249–1258 (1995).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complicat.19(3), 178–181 (2005).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med.131, 281–303 (1999).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care29(Suppl. 1), S4–S42 (2006).
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care19, 744–750 (1996).
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care27, 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• Bonora E, Corrao G, Bagnardi V et al. Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with Type 2 diabetes mellitus. Diabetologia49, 846–854 (2006).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care11(7), 567–573 (1988).
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with Type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care24(10), 1711–1721 (2001).
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol.2(1), 33–47 (2003).
   PubMedGoogle Scholar
• Triplitt C, DeFronzo RA. Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Expert Rev. Endocrinol. Metab.1, 329–341 (2006).
   PubMedGoogle Scholar
• Koda JE, Fineman M, Rink TJ et al. Amylin concentrations and glucose control. Lancet339, 1179–1180 (1992).
   PubMed Web of Science ®Google Scholar
• Koda JE, Fineman MS, Kolterman OG et al. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls [abstract 876]. Diabetes44(Suppl. 1), A238 (1995).
   Google Scholar
• Fineman MS, Giotta MP, Thompson RG et al. Amylin response following Sustacal® ingestion is diminished in Type II diabetic patients treated with insulin [abstract 556]. Diabetologia39(Suppl. 1), A149 (1996).
   PubMedGoogle Scholar
• Weyer C, Maggs DG, Young AA et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in Type 1 and Type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr. Pharm. Des.7(14), 1353–1373 (2001).
   PubMed Web of Science ®Google Scholar
• Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ.25(3), 389–397 (1999).
   PubMed Web of Science ®Google Scholar
• Young A, Moore C, Herich J et al. Neuroendocrine actions of amylin. In: The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Poyner D, Marshall I, Brain SD (Eds). Landes Bioscience, Georgetown, TX, USA, 91–102 (2000).
   Google Scholar
• Beaumont K, Kenney MA, Young AA et al. High affinity amylin binding sites in rat brain. Mol. Pharmacol.44(3), 493–497 (1993).
   PubMed Web of Science ®Google Scholar
• Riediger T, Rauch M, Jurat G et al. Cellular mechanisms of amylin activating area postrema and subfornical organ neurons [abstract P133]. Soc. Neurosci. Abstr.25(2), 2140 (1999).
   Google Scholar
• Edwards GL, Gedulin BR, Jodka C et al. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin [abstract P133]. Neurogastroenterol. Motil.10(4), 26 (1998).
   Google Scholar
• Riediger T, Zuend D, Becskei C, and Lutz TA. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol.286, R114–R122 (2004).
   Google Scholar
• Gedulin B, Jodka C, Green D et al. Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like-peptide-1 (7–36)-amide (GLP-1) [abstract 584]. Diabetologia39(Suppl. 1), A154 (1996).
   Google Scholar
• Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism46(1), 67–70 (1997).
   PubMed Web of Science ®Google Scholar
• Gedulin B, Jodka C, Percy A et al. Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats. Diabetes40(Suppl. 1), A238 (1997).
   Google Scholar
• Silvestre RA, Rodriguez-Gallardo J, Jodka C et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. J. Physiol. Endocrinol. Metab.280(3), E443–E449 (2001).
   Web of Science ®Google Scholar
• Young AA, Gedulin B, Vine W et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia38(6), 642–648 (1995).
   PubMed Web of Science ®Google Scholar
• Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism45(1), 1–3 (1996).
   PubMed Web of Science ®Google Scholar
• Rushing PA, Hagan MM, Seeley RJ et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology141(2), 850–853 (2000).
   PubMed Web of Science ®Google Scholar
• Rushing PA. Central amylin signaling and the regulation of energy homeostasis. Curr. Pharm. Des.9(10), 819–825 (2003).
   PubMed Web of Science ®Google Scholar
• Janes S, Gaeta L, Beaumont K et al. The selection of pramlintide for clinical evaluation. Diabetes45(Suppl. 2), A235 (1996).
   Web of Science ®Google Scholar
• Young AA, Vine W, Gedulin BR et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev. Res.37(4), 231–248 (1996).
   Web of Science ®Google Scholar
• SYMLIN® (pramlintide acetate) injection, package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA.
   Google Scholar
• Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu. Rev. Med.28, 119–130 (1977).
   PubMed Web of Science ®Google Scholar
• Fineman MS, Koda JE, Shen LZ et al. The human amylin analogue, pramlintide, corrects postprandial hyperglucagonemia in patients with Type 1 diabetes. Metabolism51(5), 636–641 (2002).
   PubMed Web of Science ®Google Scholar
• Fineman M, Weyer C, Maggs DG et al. The human amylin analogue, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes mellitus. Horm. Metab. Res.34, 504–508 (2002).
   PubMed Web of Science ®Google Scholar
• Nyholm B, Moller N, Gravholt CH et al. Acute effects of the human amylin analogue AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab.81(3), 1083–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Amiel SA, Heller SR, Macdonald IA et al. The effect of pramlintide on hormonal, metabolic, or symptomatic responses to insulin-induced hypoglycemia in patients with Type 1 diabetes. Diabetes Obes. Metab.7, 504–516 (2005).
   PubMed Web of Science ®Google Scholar
• Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care24, 371–381 (2001).
   PubMed Web of Science ®Google Scholar
• Nowak TV, Johnson CP, Kalbfleisch JH et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut37, 23–29 (1995).
   PubMed Web of Science ®Google Scholar
• Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type II diabetes mellitus. Gastroenterology109, 755–765 (1995).
   PubMed Web of Science ®Google Scholar
• Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in Type II diabetic patients. Diabetes Care19, 468–471 (1996).
   PubMed Web of Science ®Google Scholar
• Kong MF, King P, Macdonald IA et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia40, 82–88 (1997).
   PubMed Web of Science ®Google Scholar
• Kong MF, Stubbs TA, King P et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia41 (5), 577–583 (1998).
   PubMed Web of Science ®Google Scholar
• Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with Type 2 diabetes. Diabetologia48(5), 838–848 (2005).
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Schwartz S, Corder C et al. Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia39(4), 492–499 (1996).
   PubMed Web of Science ®Google Scholar
• Nyholm B, Ørskov L, Hove K et al. The amylin analogue pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with Type 1 diabetes mellitus. Metabolism48(7), 935–941 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson RG, Peterson J, Gottlieb A et al. Effects of pramlintide, an analogue of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes46(4), 632–636 (1997).
   PubMedGoogle Scholar
• Thompson RG, Gottlieb A, Organ K et al. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin and c-peptide concentrations in patients with Type II diabetes. Diabet. Med.14(7), 547–555 (1997).
   PubMed Web of Science ®Google Scholar
• Weyer C, Gottlieb A, Kim D et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with Type 1 diabetes: a dose timing study. Diabetes Care26, 3074–3079 (2003).
   PubMed Web of Science ®Google Scholar
• Maggs DG, Fineman M, Kornstein J et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with Type 2 diabetes: a dose-timing study. Diabetes Metab. Res. Rev.20, 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Levetan C, Want LL, Weyer C et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglycerides excursions among patients with Type 1 diabetes intensively treated with insulin pumps. Diabetes Care26(1), 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in Type 1 diabetes. Diabetes Care25(4), 724–730 (2002).
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic Medicine21(11), 1204–1212 (2004).
   PubMed Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes: a one-year randomized controlled trial. Diabetes Care26(3), 784–790 (2003).
   PubMed Web of Science ®Google Scholar
• Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with Type 2 diabetes. Diabetes Technol. Ther.4(1), 51–61 (2002).
   PubMedGoogle Scholar
• Hollander P, Ratner R, Fineman M et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with Type 2 diabetes approaching glycaemic targets. Diabetes Obes. Metab.5, 408–414 (2003).
   PubMed Web of Science ®Google Scholar
• Edelman S, Garg S, Frias J et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in Type 1 diabetes. Diabetes Care29(10), 2189–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Karl D, Philis-Tsimikas A, Darsow T et al. Pramlintide as an adjunct to insulin in patients with Type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol. Ther. (In Press).
   Google Scholar
• Guthrie R, Karl DM, Wang Y, Lorenzi G. In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with Type 1 diabetes failing to achieve glycemic targets with insulin therapy [abstract 478-P]. Diabetes54 (Suppl. 1), A118 (2005).
   Google Scholar
• Lush C, Strobel S, Zhang B, Frias J. Pramlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with Type 2 diabetes [abstract 521-P]. Diabetes55, A124 (2006).
   Google Scholar
• Frias J, Zhang B, Darsow T. Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with Type 2 diabetes [abstract 472-P]. Diabetes55, A112 (2006).
   Google Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care19(3), 257–267 (1996).
   PubMed Web of Science ®Google Scholar
• Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxdative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev.17(3), 189–212 (2001).
   PubMed Web of Science ®Google Scholar
• West IC. Radicals and oxidative stress in diabetes. Diabet. Med.17(3), 171–180 (2000).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Piconi L, Quagliaro L et al. Effects of pramlintide glucose excursions and measures of oxidative stress in patients with Type 1 diabetes. Diabetes Care28, 632–637 (2005).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Lush C, Piconi L et al. Pramlintide reduced markers of oxidative stress in the postprandial period in subjects with Type 2 diabetes [abstract 447-P]. Diabetes55, A106 (2006).
   Google Scholar
• Edelman SV, Weyer C. Unresolved challenges with insulin therapy in Type 1 and Type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol. Ther.4, 175–189 (2002).
   PubMedGoogle Scholar
• Weyer C, Fineman MS, Strobel S et al. Properties of pramlintide and insulin upon mixing. Am. J. Health Syst. Pharm.62, 816–822 (2005).
   PubMed Web of Science ®Google Scholar
• Smith SR, Blundell JE, Hompesch M et al. Pramlintide-mediated weight loss in obese subjects is accompanied by sustained reductions in 24-hour caloric intake [abstract 1722-P]. Diabetes55, A398 (2006).
   PubMed Web of Science ®Google Scholar
• Kruger DF, Gatcomb PM, Owen AK. Clinical implications of amylin and amylin deficiency. Diabetes Educator25, 389–397 (1999).
   PubMed Web of Science ®Google Scholar